StockData
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc. (PMVP) stock

PMVPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.88−0.43 (-33.13%)

Close on Nov 20, 2026Market cap $46.83MP/E –Yield –

PMV Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

PMV Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$71.28M. For fiscal 2025 it was -$73.61M. The highest annual figure on record is -$15.63M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$73.61M–
FY2024Dec 31, 2024-$51.94M–
FY2023Dec 31, 2023-$56.62M–
FY2022Dec 31, 2022-$71.74M–
FY2021Dec 31, 2021-$47.92M–
FY2020Dec 31, 2020-$32.89M–
FY2019Dec 31, 2019-$22.17M–
FY2018Dec 31, 2018-$15.63M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.58M–
Q1 FY2026Mar 31, 2026-$19.68M–
Q4 FY2025Dec 31, 2025-$17.20M–
Q3 FY2025Sep 30, 2025-$19.82M–
Q2 FY2025Jun 30, 2025-$18.31M–
Q1 FY2025Mar 31, 2025-$18.27M–
Q4 FY2024Dec 31, 2024-$16.72M–
Q3 FY2024Sep 30, 2024-$16.84M–
Q2 FY2024Jun 30, 2024-$1.60M–
Q1 FY2024Mar 31, 2024-$16.78M–
Q4 FY2023Dec 31, 2023-$12.28M–
Q3 FY2023Sep 30, 2023-$15.70M–
Q2 FY2023Jun 30, 2023-$13.47M–
Q1 FY2023Mar 31, 2023-$15.17M–
Q4 FY2022Dec 31, 2022-$16.96M–
Q3 FY2022Sep 30, 2022-$18.81M–
Q2 FY2022Jun 30, 2022-$17.18M–
Q1 FY2022Mar 31, 2022-$18.79M–
Q4 FY2021Dec 31, 2021-$12.29M–
Q3 FY2021Sep 30, 2021-$12.90M–
Q2 FY2021Jun 30, 2021-$9.71M–
Q1 FY2021Mar 31, 2021-$13.02M–
Q4 FY2020Dec 31, 2020-$10.37M–
Q3 FY2020Sep 30, 2020-$7.43M–
Q2 FY2020Jun 30, 2020-$6.90M–
Q1 FY2020Mar 31, 2020-$8.19M–
Q4 FY2019Dec 31, 2019-$5.13M–

More PMV Pharmaceuticals figures

See a number that looks wrong?